Sijme Zeilemaker

BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands.

2-BBB Medicines BV is a Dutch pharmaceutical company located in Leiden, NL. The private company was founded as a spin-off from the Blood-Brain Barrier Research Group of the Leiden Academic Center for Drug Research (LACDR) at Leiden University. The company specializes in developing medicines for the treatment of brain and eye diseases. The company uses their proprietary CNS targeted liposome formulation, called G-Technology®, to safely enhance drug delivery to the brain and eye. 2-BBB Medicines has two programs in clinical development for the treatment of brain cancer and neuro-inflammatory diseases.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.